Comparative Pharmacology
Head-to-head clinical analysis: ABSORICA versus ACCUTANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ABSORICA versus ACCUTANE.
ABSORICA vs ACCUTANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isotretinoin is a retinoid that binds to nuclear retinoic acid receptors (RARs) and retinoid X receptors (RXRs), modulating gene expression involved in cell differentiation, proliferation, and apoptosis. It reduces sebaceous gland size and sebum production, inhibits sebocyte differentiation, and has anti-inflammatory effects.
Retinoid that reduces sebum production, normalizes follicular keratinization, and decreases Propionibacterium acnes growth by binding to nuclear retinoic acid receptors, altering gene expression.
0.5-1 mg/kg/day orally in 2 divided doses for 15-20 weeks, then 0.1-0.5 mg/kg/day as maintenance.
Isotretinoin 0.5-1 mg/kg/day orally in 2 divided doses for 15-20 weeks.
None Documented
None Documented
Terminal elimination half-life: 21-29 hours in adults; 33 hours in pediatric patients. Steady-state reached in 7-10 days.
Terminal elimination half-life of isotretinoin is 10-20 hours. The half-life of the major metabolite, 4-oxo-isotretinoin, is 11-50 hours. The long half-life of the metabolite may contribute to sustained clinical effects.
Renal (approx. 65% as metabolites) and biliary (approx. 35% as metabolites). Less than 1% excreted unchanged.
Renal and biliary: approximately equal amounts of metabolites are excreted in urine and feces. Unchanged drug is not excreted. Major metabolites: 4-oxo-isotretinoin, tretinoin, 4-oxo-tretinoin. Renal excretion of metabolites accounts for ~65-83% of the dose; fecal excretion accounts for the remainder.
Category C
Category C
Retinoid
Retinoid